Aniracetam Capsules & Powder
- Aniracetam (1-P-Anisoyl-2-Pyrrolidinone) is an organic compound in the class of benzoic acids and derivatives (ref)*
- Synthesized to be fat soluble (ref)*
- Assured Purity: Rigorously tested for quality & purity by third-party Certificate of Analysis*
Aniracetam Chemical Properties
Aniracetam’s molecular formula is C12H13NO3 and it has a molecular mass of 219.24 g/mol.
Aniracetam is also known as 1-P-Anisoyl-2-Pyrrolidinone and the CAS Number is 72432-10-1 (1).
Pure Nootropics offers Aniracetam in 750 mg capsules in both 30 and 60 count bottles.
Bulk powder is available in 75 gram and 200 gram quantities.
For further information, please see our References Tab above.
Notice: This product is a chemical compound. All chemicals have risks. This product is not approved by the FDA. Please research and understand the associated risks before handling. None of the information provided in our references are meant to be considered comprehensive or representative of the entire body of research on this compound. Please consult a qualified professional if you are unsure of how to handle this chemical. Misuse of this product may result in adverse reactions.
The references below are not meant to imply that any of our products treat, cure, or diagnose any disease or human condition. This product is sold as a research chemical and is for research purposes only; we recommend consulting a professional about how to handle this chemical. References to clinical studies and pre-clinical studies may use varying dosages and may not represent the dosages or subsequent results of products we sell; however, the references provided are pertinent to the subject supplement itself. References provided are intended for research and informational purposes only and do not represent the entire body of knowledge available on the subject(s) referenced; nor do they represent all possible outcomes associated with the subject(s) referenced including, but not limited to, adverse effects, precautions, or chemical interactions within the human body. The Content provided on this website is not intended to be a replacement for professional medical advice, treatment or diagnosis. Never ignore the advice of a medical professional or delay in attaining professional advice because of information or impressions you gather on this website. Choosing to rely on any information provided by the Content of this website is solely at your own risk. We encourage our audience to do their own research beyond the resources we have provided so your decision is as educated as possible.
• Aniracetam (1-P-Anisoyl-2-Pyrrolidinone) is an organic compound in the class of benzoic acids and derivatives (ref). It interacts between the serotonergic, dopaminergic and cholinergic systems (ref)*
“Aniracetam.” Drug Bank, www.drugbank.ca/drugs/DB04599.
“Aniracetam.” PubChem Open Chemistry Database, https://pubchem.ncbi.nlm.nih.gov/compound/2196#section=Pharmacology-and-Biochemistry.
• Synthesized to be fat soluble (ref): Fat-soluble compounds can access the brain via the blood-brain-barrier (ref)*
“Aniracetam,” Examine.com, published on 29 June 2014, last updated on 14 June 2018, https://examine.com/supplements/aniracetam/.
Ronald E. Baynes, Kelly J. Dix, Jim E. Riviere, Chapter 6 – Distribution and Pharmacokinetics Models**This chapter was editorially abbreviated and reformatted from K.J. Dix, 2001, Absorption, distribution and pharmacokinetics, Chapter 24 in Handbook of Pesticide Toxicology (R. Krieger, Ed.), 2nd edition, Academic Press, San Diego., Editor(s): Ernest Hodgson,dPesticide Biotransformation and Disposition, Academic Press,2012,Pages 117-147,ISBN 9780123854810, https://doi.org/10.1016/B978-0-12-385481-0.00006-X.
1. “Aniracetam.” PubChem Open Chemistry Database,
2. “Aniracetam,” Examine.com, published on 29 June 2014, last updated on 14 June 2018, https://examine.com/supplements/aniracetam/.
3. Schlappi, Bernhard, et al. “Aniracetam: Toxicological Profile of a Chemical Derivative of 2-Pyrrolidinone.” Drug Investigation, vol. 5, no. 1, June 1993, pp. 50–67., http://link.springer.com/article/10.1007/BF03258427.
4. Wijayawardhane, Nayana. THERAPEUTIC EFFECTS OF ANIRACETAM ON COGNITIVE DEFICITS INDUCED BY ETHANOL TERATOGENICITY: A NOVEL TREATMENT APPROACH THROUGH SYNAPTIC AMPA RECEPTOR MODULATION. Auburn University Dissertation. May 10, 2007. https://etd.auburn.edu/xmlui/bitstream/handle/10415/822/WIJAYAWARDHANE_NAYANAKANTHI_21.pdf?sequence=1&isAllowed=y.
5. Gumru, Salih, and Feyza Aricoglu. “Ampakines: Selective AMPA Receptor Modulators with Potential Benefits.” Marmara University, School of Pharmacy Department of Pharmacology and Psychopharmacology Research Unit, Istanbul, Turkey, 21 Nov. 2012, pdfs.semanticscholar.org/ffad/a3b5abaf45e96723846d0e8424e822ecdd19.pdf.
6. Schlappi, Bernhard, et al. “Aniracetam: Toxicological Profile of a Chemical Derivative of 2-Pyrrolidinone.” Drug Investigation, vol. 5, no. 1, June 1993, pp. 50–67., link.springer.com/article/10.1007/BF03258427.